Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to Proactive London's Andrew Scott after announcing that US biotech Codagenix Inc has commissioned its hVIVO arm to carry out a first-in-human trial of a nasal vaccine for coronavirus. The phase I study of 48 healthy young adults will take place at hVIVO's state-of-the-art quarantine facility in London’s Whitechapel.
28 Jul 20